BMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Mergers and Acquisitions

Pre-Open Stock Movers 09/02: (SURG) (VRA) (WMGI) Higher; (RJET) (DGLY) (HTWR) Lower (more...)September 2, 2015 9:23 AM Valeant Pharmaceuticals To Acquire Synergetics USASeptember 2, 2015 8:02 AM Valeant Pharma (VRX) to Acquire Synergetics USA (SURG) for $6.50/Share + MilestonesSeptember 2, 2015 8:02 AM Synergetics USA to Be Acquired by Valeant PharmaceuticalsSeptember 2, 2015 8:00 AM AstraZeneca (AZN) Enters Brodalumab Licensing Agreement with Valeant (VRX)September 1, 2015 6:17 AM Valeant picks up AstraZeneca psoriasis drug after Amgen exit September 1, 2015 2:31 AM Valeant And AstraZeneca To Partner On BrodalumabSeptember 1, 2015 2:00 AM